A Phase I Study of Donor BPX-501 T Cell Infusion for Adults with
Recurrent or Minimal Residual Disease Hematologic Malignancies
This research study will test whether immune cells, called T cells, when grown in a lab and then transplanted, can help the immune system recover faster and kill tumor cells.
In addition, this study will evaluate the safety of the infusion of escalating doses of the drug Rimiducid.
Other high-risk hematologic malignancies eligible for stem cell transplantation
This study accepts the following diseases: Leukemia, Myelodysplastic Syndromes, Lymphomas, Multiple myeloma, other high-risk hematologic malignancies eligible for stem cell transplantation. One of the aforementioned diseases must be present and evidence of recurrent disease that presents more than 100 days post-transplant, or minimal residual disease (MRD) that presents more than 30 days after matched or mismatched related Hematopoietic stem cell transplantation (HSCT) must also be present.
18 - 65
Healthy Volunteers Needed
Duration of Participation
The treatment phase of the study is expected to last at least 60 days. After the first year participants will be asked to return to the clinic every 3 months until 2 years after the first infusion, then annually to year 5, then for 10 more years for a total of 15 years after the first infusion.
Knight Cancer Intake Center: (503)494-7999
Clinical Trials Information Line: (503)494-1080 or firstname.lastname@example.org
Bellicum Pharmaceuticals, Inc.